Treatment of Children With B-Cell Non-Hodgkin Lymphoma in a Low-Income Country

Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Pediatric Blood & Cancer (Impact Factor: 2.39). 04/2011; 56(4):560-7. DOI: 10.1002/pbc.22905
Source: PubMed


An adapted LMB 96 derived protocol for B-cell non-Hodgkin lymphoma (NHL) was implemented at the pediatric oncology unit of the Children Welfare Teaching Hospital in Baghdad (Iraq) from 2000 to present. The purpose was to evaluate the feasibility and efficacy of this intensive therapeutic regimen in a limited resource country.
Patients <15 years of age with high grade B-cell NHL were included. A modified LMB 96 regimen was employed with a reduction of cyclophosphamide and methotrexate dosages due to inadequate laboratory facilities and supportive care.
Between 2000 and 2005, 261 children with non-lymphoblastic NHL were registered; 239 were eligible for the analysis. Two patients had stage I disease, 20 stage II, 179 stage III, and 38 stage IV. Fifty-two patients (22%) had bulky disease. Twelve children were assigned to therapeutic group A (low risk), 184 to group B (intermediate risk), and 43 to group C (high risk). One hundred and eighty-four patients (77%) had a complete response after the COP pre-phase. Sixty-nine patients (29%) died during treatment. Twenty-nine patients abandoned treatment. At 24 months, the overall survival rate of the entire patient population was 66% (CI 95%: 62.2-70.6) and the event-free survival rate 53.3% (CI 95%: 50.0-56.8).
The treatment schedule proved effective, but the treatment-related mortality due to infections and metabolic complications was very high owing to the limited supportive care available. The high rate of treatment abandonment was also an important cause of failure, especially for children living far away from the hospital.

Download full-text


Available from: Mazin Faisal Al-jadiry, Jul 18, 2014
1 Follower
39 Reads
  • Source
    • "Treatment of acute myeloid leukaemia involves combination chemotherapy to control systemic and bone marrow disease. The high rate of treatment abandonment, due to unaffordability and patients living long distances from facilities, the inability to provide optimum treatment due to unavailability of medication, and treatment-related complications due to inadequate supportive care, limit the survival prospects of patients with lymphoreticular neoplasms [19,20,85,86]. Given the growing burden of these cancers, health service investments in accurate staging, immunohistochemistry, radiotherapy and essential chemotherapeutic drugs are critical to their improved control. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Asia accounts for 60% of the world population and half the global burden of cancer. The incidence of cancer cases is estimated to increase from 6.1 million in 2008 to 10.6 million in 2030, due to ageing and growing populations, lifestyle and socioeconomic changes. Striking variations in ethnicity, sociocultural practices, human development index, habits and dietary patterns are reflected in the burden and pattern of cancer in different regions. The existing and emerging cancer patterns and burden in different regions of Asia call for political recognition of cancer as an important public health problem and for balanced investments in public and professional awareness. Prevention as well as early detection of cancers leads to both better health outcomes and considerable savings in treatment costs. Cancer health services are still evolving, and require substantial investment to ensure equitable access to cancer care for all sections of the population. In this review, we discuss the changing burden of cancer in Asia, along with appropriate management strategies. Strategies should promote healthy ageing via healthy lifestyles, tobacco and alcohol control measures, hepatitis B virus (HBV) and human papillomavirus (HPV) vaccination, cancer screening services, and vertical investments in strengthening cancer healthcare infrastructure to improve equitable access to services.
    BMC Medicine 01/2014; 12(1):3. DOI:10.1186/1741-7015-12-3 · 7.25 Impact Factor
  • Source
    • "However, dose and administration schedules vary considerably. Some low-income countries such as Brazil, Argentina, Lebanon and Iraq have reported improved survival rates of children with B-NHL, although the MTX dose did not exceed 2 g/m2(17,18,28). The present study demonstrates that it is possible to obtain satisfactory results with the use of MTX at a dose of 0.5 g/m2, because only two patients relapsed and the other ten died of infectious or metabolic complications before or at the beginning of treatment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Burkitt's lymphoma is the most common subtype of non-Hodgkin lymphoma in children. The aim of this study was to characterize the clinical course and prognostic factors of children and adolescents with Burkitt's lymphoma treated in the Hematology Unit of Hospital das Clínicas, Universidade Federal de Minas Gerais (UFMG). A retrospective cohort study was made of 50 consecutive cases of children and adolescents aged 16 years or less with Burkitt's lymphoma admitted between January 1981 and December 2007. Prognostic factors associated with death were evaluated using the Kaplan-Meier method and compared by the two-tailed log-rank test. The median age at diagnosis was 4.7 years. Most patients had abdominal tumors (66.7%) and advanced disease (68.9%) at diagnosis. Thirty-eight patients (84.4%) achieved complete clinical remission and 33 (73.3%) were alive at the first remission. Twelve children (26.7%) died. The median follow-up was 35 months with the probability of overall survival being 73% (89.2% and 35.7% for patients with uric acid < 7 mg/dL and ≥ 7.0 mg/dL, respectively - p-value < 0.001). Uric acid was the only significant prognostic factor at diagnosis. Our findings confirm the favorable prognosis of children with Burkitt's lymphoma even when treated with intermediate doses of methotrexate (500 mg/m2). Survival was significantly lower for individuals with concentrations of uric acid > 7 mg/dL.
    03/2012; 34(5):361-6. DOI:10.5581/1516-8484.20120093
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lymphoblastic lymphoma (LBL) is a neoplasm of lymphoblasts. The condition is predominantly lymph node-based disease arising from immature T cells in 85-90% of cases and immature B cells in the remainder. The lymphoma is aggressive, progresses rapidly, and often presenting as stage IV disease in more than 70% of patients. This disease makes up approximately 20% of childhood NHL. To show case the management of childhood lymphoblastic lymphoma and the handicap faced by the oncologists and pathologists. A review of the index case was carried out at the paediatric department of Federal Medical Centre, Bida, Nigeria. This review took into cognisance patient's demographic bio data, case history, general and physical examination, various investigations, methods of diagnosis and the type treatment. A comprehensive analysis and account of events before and after the commencement of chemotherapy were also reviewed. This case identifies a 5 year old girl with aggressive malignant lymphoma; lymphoblastic type and the myriad of limitations faced by oncologists and pathologists in the management of haematological malignancies. Socio-cultural, financial (cost implications for the patient for both investigative and therapeutic interventions), inadequate resources and facilities were identified as some of the constraints leading to inadequate management and poor outcome in patients with this condition. Given the limitations associated with the management of cancers in this part of the world, efforts on the part of government and non-governmental agencies are necessary to strengthen and upgrade the existing facilities in various hospitals. The social welfare departments of tertiary hospitals should be adequately funded to meet the demand of this group of patients.
    African health sciences 06/2011; 11(2):290-5. DOI:10.4314/ahs.v11i2.68461 · 0.72 Impact Factor
Show more